(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
6 November 2014 (06.11.2014)

WIPO | PCT

(10) International Publication Number
WO 2014/179627 A3

(51) International Patent Classification:
C12N 15/113 (2010.01)

(21) International Application Number:
PCT/US2014/036463

(22) International Filing Date:
1 May 2014 (01.05.2014)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:

61/818,442	1 May 2013 (01.05.2013)	US
61/823,826	15 May 2013 (15.05.2013)	US
61/843,887	8 July 2013 (08.07.2013)	US
61/871,673	29 August 2013 (29.08.2013)	US
61/880,790	20 September 2013 (20.09.2013)	US
61/976,991	8 April 2014 (08.04.2014)	US
61/986,867	30 April 2014 (30.04.2014)	US

(71) Applicant: **ISIS PHARMACEUTICALS, INC.** [US/US]; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(72) Inventors: **PRAKASH, Thazha, P.**; 2855 Gazelle Court, Carlsbad, CA 92010 (US). **SETH, Punit, P.**; 2855 Gazelle Court, Carlsbad, CA 92010 (US). **SWAYZE, Eric, E.**; 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(74) Agents: **TUNG, Jeffrey, J.** et al.; Isis Pharmaceuticals, Inc., 2855 Gazelle Court, Carlsbad, CA 92010 (US).

(81) Designated States *(unless otherwise indicated, for every kind of national protection available)*: AE, AG, AL, AM, AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ, CA, CH, CL, CN, CO, CR, CU, CZ, DE, DK, DM, DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT, HN, HR, HU, ID, IL, IN, IR, IS, JP, KE, KG, KN, KP, KR, KZ, LA, LC, LK, LR, LS, LT, LU, LY, MA, MD, ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, SM, ST, SV, SY, TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, ZA, ZM, ZW.

(84) Designated States *(unless otherwise indicated, for every kind of regional protection available)*: ARIPO (BW, GH, GM, KE, LR, LS, MW, MZ, NA, RW, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Published:

— *with international search report (Art. 21(3))*

— *with sequence listing part of description (Rule 5.2(a))*

— *with information concerning authorization of rectification of an obvious mistake under Rule 91.3 (b) (Rule 48.2(i))*

(88) Date of publication of the international search report:
16 April 2015

(15) Information about Correction:

Previous Correction:
see Notice of 26 February 2015

(54) Title: COMPOSITIONS AND METHODS FOR MODULATING HBV AND TTR EXPRESSION

(57) Abstract: Provided herein are oligomeric compounds with conjugate groups. In certain embodiments, the oligomeric compounds are conjugated to N-Acetylgalactosamine. In certain embodiments, the present disclosure provides conjugated antisense compounds. In certain embodiments, the present disclosure provides conjugated antisense compounds comprising an antisense oligonucleotide complementary to a nucleic acid transcript of transthyretin (TTR).

WO 2014/179627 A3